|1.||Brinkmann, Volker: 27 articles (11/2014 - 06/2002)|
|2.||Kappos, Ludwig: 23 articles (12/2015 - 09/2006)|
|3.||Chun, Jerold: 13 articles (05/2015 - 01/2006)|
|4.||Hla, Timothy: 13 articles (12/2014 - 11/2003)|
|5.||Hartung, Hans-Peter: 12 articles (09/2015 - 02/2010)|
|6.||Chiba, Kenji: 12 articles (08/2015 - 12/2005)|
|7.||Francis, Gordon: 12 articles (04/2015 - 11/2010)|
|8.||Rosen, Hugh: 11 articles (10/2015 - 01/2006)|
|9.||Spiegel, Sarah: 11 articles (10/2015 - 12/2004)|
|10.||Cohen, Jeffrey A: 11 articles (06/2015 - 02/2010)|
12/01/2013 - "The efficacy of the innovative oral drug fingolimod has been proven in the largest study program in multiple sclerosis (MS) demonstrating reduced relapse and reduced disability progression in relapsing-remitting MS patients. "
12/01/2013 - "2-Amino-2-[2-(4-octylphenyl)]-1,3-propanediol hydrochloride (FTY720) is a potent immunosuppressant which has been approved by the Food and Drug Administration (FDA) as a new treatment for multiple sclerosis. "
03/15/2013 - "Therefore, FTY720 may be a potent therapeutic agent for not only multiple sclerosis but also other neurologic diseases associated with microglial activation."
05/01/2008 - "A recent Phase II study has demonstrated that oral FTY720 is effective in reducing disease activity in relapsing multiple sclerosis with a favorable adverse-effect profile. "
05/01/2014 - "In the present study, we aimed to investigate whether FTY720, the first approved oral therapy for multiple sclerosis, may be effective in HD models and eventually constitute an alternative therapeutic approach for the treatment of the disease. "
|2.||Relapsing-Remitting Multiple Sclerosis
01/01/2015 - "Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis."
02/01/2012 - "Fingolimod (Gilenya--Novartis) is a new treatment for patients with highly active relapsing-remitting multiple sclerosis. "
06/01/2014 - "Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial."
01/01/2014 - "A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). "
01/01/2011 - "Results from Phase II and III clinical trials provide robust evidence of the efficacy of fingolimod in relapsing-remitting multiple sclerosis. "
|3.||Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental)
09/21/2012 - "NIBR-0213 showed comparable therapeutic efficacy to fingolimod in experimental autoimmune encephalomyelitis (EAE), a model of human MS. These data provide convincing evidence that S1P(1) antagonists are effective in EAE. "
07/01/2012 - "In experimental autoimmune encephalomyelitis, the therapeutic efficacy of fingolimod is not only associated with a reduced entry of inflammatory cells into the nervous system, but also with a direct effect mostly on astroglial cells. "
01/01/2016 - "Fingolimod ameliorates the development of experimental autoimmune encephalomyelitis by inhibiting Akt-mTOR axis in mice."
02/01/2010 - "FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses."
12/01/2015 - "In vitro and ex vivo immunologic studies coupled with flow cytometry were performed to evaluate the action of fingolimod on lipopolysaccharide (LPS)-induced expression of activation markers in human monocytes from healthy participants, participants with untreated MS, and participants with fingolimod-treated MS. In vivo administration of fingolimod during experimental autoimmune encephalomyelitis (EAE) was established to verify the activation state of splenic, CNS infiltrating, and CNS resident myeloid cells ex vivo at flow cytometer. "
|4.||Autoimmune Diseases (Autoimmune Disease)
12/01/2005 - "FTY720 has been shown to be highly effective in experimental allotransplantation models and autoimmune disease models. "
01/01/2012 - "Fingolimod therefore represents the first oral drug for the treatment of this autoimmune disease of the central nervous system. "
01/01/2008 - "Due to its mode of action, FTY720 effectively prevents transplant rejection and is active in various autoimmune disease models. "
05/25/2007 - "Short exposures to FTY720 afford long term protection in lymphoproliferative and autoimmune disease models, presumably by inducing apoptosis in subsets of cells essential for pathogenesis. "
04/01/2009 - "FTY720 has shown to be highly effective in experimental allograft models and autoimmune disease models. "
11/13/2009 - "We found that treatment with FTY720 (1mg/kg) reduced lesion size and improved neurological function after experimental stroke in mice, decreased the numbers of infiltrating neutrophils, activated microglia/macrophages in the ischemic lesion and reduced immunohistochemical features of apoptotic cell death in the lesion."
01/01/2015 - "Delivery of FTY720 that removes S1P signaling with chronic exposure reduced damage in both initial and S1P-potentiated M/R-challenged brain, while reducing stroke markers like TNF-α. "
12/23/2014 - "We conclude that in patients with acute and anterior cerebral circulation occlusion stroke, oral fingolimod within 72 h of disease onset was safe, limited secondary tissue injury from baseline to 7 d, decreased microvascular permeability, attenuated neurological deficits, and promoted recovery. "
12/23/2014 - "Impact of an immune modulator fingolimod on acute ischemic stroke."
09/01/2014 - "Patients treated with fingolimod exhibited a reduction of neurologic impairment compared with control individuals, regained a Glasgow Coma Scale score of 15 by day 7 (100% vs 50%, P = .01), and had a National Institutes of Health Stroke Scale score reduction of 7.5 vs 0.5 (P < .001). "
|3.||sphingosine 1-phosphate (sphingosine-1-phosphate)
|7.||interferon beta 1a
|8.||Amyloid (Amyloid Fibrils)
|1.||Homologous Transplantation (Allograft)
|3.||Transplantation (Transplant Recipients)
|4.||Heterologous Transplantation (Xenotransplantation)